Specialty pharmaceuticals maker Depomed has replaced its chief executive and named two new directors to its board after nearly a year of activist pressure from Starboard Value LP.
WSJ.com: US Business, Wall Street Journal: Business
Tue, 03/28/2017 - 2:49pm
Specialty pharmaceuticals maker Depomed has replaced its chief executive and named two new directors to its board after nearly a year of activist pressure from Starboard Value LP.